Reply by Authors: Carcinogenic Effects of Nitrosodimethylamine Contamination in Ranitidine: Defining the Relationship with Renal Malignancies

Abstract

We thank the reviewers for providing these editorial comments that highlight the question posed to urologists, the FDA, and patients as to whether ranitidine increases the risk of renal malignancies.1,2 We believe preclinical data and limited population data demonstrate an association between this now-recalled medication and kidney cancer but not causation.3 As this issue spills into the legal system and regulatory bodies, it is incumbent on all the parties involved to carefully evaluate the dynamic stream of information and seek out further answers on this topic.